(RLYP) (RLYP) Stock Price, News & Analysis

Company Overview

Relypsa, Inc. is a United States-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of polymer-based medicines. The Company's technology platform includes a high-throughput chemistry process, enabling the Company to explore various potential polymer medicines for each disease it seeks to address. Its polymers are non-absorbed, meaning they act within the gastrointestinal tract and do not get absorbed into the bloodstream or other parts of the body. Its polymer technology may be able to address many health conditions in need of viable treatment options. Its VELTASSA (patiromer) for oral suspension is a commercialized medicine resulting from its polymer technology platform. VELTASSA is a potassium binder approved for the treatment of hyperkalemia. Available in powder form, VELTASSA is mixed with water and taken daily. VELTASSA's spherical beads bind to potassium in exchange for calcium, primarily in the colon.

Key Stats

• Today's Range: $31.99 to $31.99
• 50-Day Range: N/A
• 52-Week Range: $10.26 to $32.12
• Volume: N/A
• Average Volume: 2.93 million shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

RLYP Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of (RLYP) own?

Based on aggregate information from My MarketBeat watchlists, some other companies that (RLYP) investors own include Bristol-Myers Squibb (BMY), Royalty Pharma (RPRX), Synergy Pharmaceuticals (SGYP), Akorn (AKRX), Novavax (NVAX), Verastem (VSTM) and Skechers U.S.A. (SKX).

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:RLYP
• CUSIP: N/A
• CIK: 1416792
• Web: www.relypsa.com
• Phone: +1-650-4219500
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A